GSK follows Pfizer in meningococcal vaccine race with new FDA nod

GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer. Penmenvy was approved Friday for children and young adults ages 10 to 25. Chief scientific officer Tony ...